




RealRate

PHARMACEUTICAL 2020

Axsome Therapeutics Inc.
Rank 115 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

Axsome Therapeutics Inc. Rank 115 of 362

The relative strengths and weaknesses of Axsome Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Axsome Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 316% points. The greatest weakness of Axsome Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is -62%, being 241% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	220,379
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,495
Liabilities, Non-Current	17,333
Other Assets	140
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,100
Property and Equipment	31
Research and Development	53,647
Revenues	0
Selling, General and Administrative Expense	13,598

Output Variable	Value in 1000 USD
Assets	220,550
Liabilities	41,827
Expenses	67,245
Stockholders Equity	178,722
Net Income	-68,345
Comprehensive Net Income	-68,345
Economic Capital Ratio	-62%

